Entera Bio Ltd. 8K

Entera Bio Ltd. reported Q2 2026 results, secured FDA alignment on a registrational Phase 3 trial for EB613, and raised $275 million in an oversubscribed private placement to fund its oral peptide pipeline through EB613’s anticipated NDA submission.

Entera Bio Ltd. filed a Form 8-K to furnish its second quarter 2026 financial results and provide business updates, highlighting FDA alignment on the design of a single 12‑month registrational Phase 3 trial for EB613 to support an NDA under the 505(b)(2) pathway, continued progress across its oral peptide pipeline (EB613, EB612, EB618), and significant financing activities, including an oversubscribed $275 million private placement in July 2026 led by BVF Partners that is expected to fund the Phase 3 EB613 program through topline data and anticipated NDA submission and extend the company’s cash runway into 2030; the company reported a Q2 2026 net loss of $7.3 million on increased R&D spending tied to EB613 and its OPKO collaboration and recorded a non‑cash fair value remeasurement of pre‑funded warrants issued in an April 2026 BVF‑led private placement.

Filing Facts

CIK

1638097

Ticker

-

Form

8K

Source Type

sec

Accession

0001178913-26-003946

Alert Tier

7